NEURAXIS INC (NRXS) Fundamental Analysis & Valuation

NYSEARCA:NRXS • US64134X2018

5.71 USD
-0.17 (-2.89%)
At close: Mar 6, 2026
5.6 USD
-0.11 (-1.93%)
After Hours: 3/6/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NRXS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, NRXS scores 3 out of 10 in our fundamental rating. NRXS was compared to 184 industry peers in the Health Care Equipment & Supplies industry. While NRXS seems to be doing ok healthwise, there are quite some concerns on its profitability. NRXS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. NRXS Profitability Analysis

1.1 Basic Checks

  • In the past year NRXS has reported negative net income.
  • NRXS had a negative operating cash flow in the past year.
  • NRXS had negative earnings in each of the past 5 years.
  • In the past 5 years NRXS always reported negative operating cash flow.
NRXS Yearly Net Income VS EBIT VS OCF VS FCFNRXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

  • NRXS has a worse Return On Assets (-110.11%) than 82.07% of its industry peers.
  • NRXS has a Return On Equity of -183.49%. This is in the lower half of the industry: NRXS underperforms 72.28% of its industry peers.
Industry RankSector Rank
ROA -110.11%
ROE -183.49%
ROIC N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NRXS Yearly ROA, ROE, ROICNRXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

  • NRXS's Gross Margin of 84.82% is amongst the best of the industry. NRXS outperforms 93.48% of its industry peers.
  • In the last couple of years the Gross Margin of NRXS has grown nicely.
  • The Profit Margin and Operating Margin are not available for NRXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
NRXS Yearly Profit, Operating, Gross MarginsNRXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NRXS Health Analysis

2.1 Basic Checks

  • NRXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NRXS has more shares outstanding than it did 1 year ago.
  • NRXS has a better debt/assets ratio than last year.
NRXS Yearly Shares OutstandingNRXS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M
NRXS Yearly Total Debt VS Total AssetsNRXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

  • Based on the Altman-Z score of -0.89, we must say that NRXS is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -0.89, NRXS perfoms like the industry average, outperforming 44.02% of the companies in the same industry.
  • There is no outstanding debt for NRXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.89
ROIC/WACCN/A
WACC10.14%
NRXS Yearly LT Debt VS Equity VS FCFNRXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M -4M -6M

2.3 Liquidity

  • NRXS has a Current Ratio of 2.82. This indicates that NRXS is financially healthy and has no problem in meeting its short term obligations.
  • NRXS's Current ratio of 2.82 is in line compared to the rest of the industry. NRXS outperforms 55.98% of its industry peers.
  • NRXS has a Quick Ratio of 2.76. This indicates that NRXS is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 2.76, NRXS is doing good in the industry, outperforming 62.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.82
Quick Ratio 2.76
NRXS Yearly Current Assets VS Current LiabilitesNRXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. NRXS Growth Analysis

3.1 Past

  • NRXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.66%, which is quite impressive.
  • Looking at the last year, NRXS shows a very strong growth in Revenue. The Revenue has grown by 41.77%.
  • The Revenue has been decreasing by -0.42% on average over the past years.
EPS 1Y (TTM)66.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
Revenue 1Y (TTM)41.77%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%46.57%

3.2 Future

  • NRXS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.87% yearly.
  • Based on estimates for the next years, NRXS will show a quite strong growth in Revenue. The Revenue will grow by 17.08% on average per year.
EPS Next Y-855%
EPS Next 2Y-133.45%
EPS Next 3Y-11.87%
EPS Next 5YN/A
Revenue Next Year-70.39%
Revenue Next 2Y-14.59%
Revenue Next 3Y17.08%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NRXS Yearly Revenue VS EstimatesNRXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M 15M
NRXS Yearly EPS VS EstimatesNRXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

0

4. NRXS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NRXS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NRXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NRXS Price Earnings VS Forward Price EarningsNRXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NRXS Per share dataNRXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

  • NRXS's earnings are expected to decrease with -11.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-133.45%
EPS Next 3Y-11.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NRXS Dividend Analysis

5.1 Amount

  • NRXS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NRXS Fundamentals: All Metrics, Ratios and Statistics

NEURAXIS INC

NYSEARCA:NRXS (3/6/2026, 8:04:00 PM)

After market: 5.6 -0.11 (-1.93%)

5.71

-0.17 (-2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10
Earnings (Next)03-20
Inst Owners13.45%
Inst Owner Change94.36%
Ins Owners18.9%
Ins Owner Change0%
Market Cap60.81M
Revenue(TTM)3.22M
Net Income(TTM)-7.80M
Analysts82.5
Price Target7.14 (25.04%)
Short Float %2.13%
Short Ratio0.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.01%
Min EPS beat(2)-34.8%
Max EPS beat(2)-5.21%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-55.37%
Min Revenue beat(2)-99.88%
Max Revenue beat(2)-10.86%
Revenue beat(4)0
Avg Revenue beat(4)-67.3%
Min Revenue beat(4)-99.88%
Max Revenue beat(4)-10.86%
Revenue beat(8)0
Avg Revenue beat(8)-69.11%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.8%
PT rev (3m)19.15%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.9
P/FCF N/A
P/OCF N/A
P/B 14.3
P/tB 14.61
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.3
BVpS0.4
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -110.11%
ROE -183.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.82%
FCFM N/A
ROA(3y)-1140.93%
ROA(5y)-815%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.51%
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.14%
Cap/Sales 0.92%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.82
Quick Ratio 2.76
Altman-Z -0.89
F-Score4
WACC10.14%
ROIC/WACCN/A
Cap/Depr(3y)133.32%
Cap/Depr(5y)94.99%
Cap/Sales(3y)2.06%
Cap/Sales(5y)1.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.62%
EPS Next Y-855%
EPS Next 2Y-133.45%
EPS Next 3Y-11.87%
EPS Next 5YN/A
Revenue 1Y (TTM)41.77%
Revenue growth 3Y-0.42%
Revenue growth 5YN/A
Sales Q2Q%46.57%
Revenue Next Year-70.39%
Revenue Next 2Y-14.59%
Revenue Next 3Y17.08%
Revenue Next 5YN/A
EBIT growth 1Y17.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1096.17%
EBIT Next 3Y-16.84%
EBIT Next 5YN/A
FCF growth 1Y-160.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.44%
OCF growth 3YN/A
OCF growth 5YN/A

NEURAXIS INC / NRXS FAQ

What is the fundamental rating for NRXS stock?

ChartMill assigns a fundamental rating of 3 / 10 to NRXS.


Can you provide the valuation status for NEURAXIS INC?

ChartMill assigns a valuation rating of 0 / 10 to NEURAXIS INC (NRXS). This can be considered as Overvalued.


What is the profitability of NRXS stock?

NEURAXIS INC (NRXS) has a profitability rating of 1 / 10.